Beta Drugs IPO

Beta Drugs IPOBusiness description from prospectus – Beta Drugs is primarily engaged in the manufacturing of oncology products. Its products range from anticancer tablets, capsules, injections and lyophilized injections. The company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. As on March 31, 2017, the company had a portfolio of over 50 products products catering to various oncology diseases including breast, brain, bone, lung, mouth, head & neck, prostate, haematology, cervics, oeaophagus etc. It has increased its product range, starting from 35 in 2015-16 to 50 active products in 2016-17. The company’s oncology portfolio includes key brands like Admine, Adgef, Addplatin, Erlotad etc.

Promoters of Beta Drugs – Vijay Kumar Batra

Beta Drugs IPO details

Subscription Dates 29 Sep – 4 Oct 2017
IPO Price band INR85 per share
Fresh issue 2,296,000 shares (INR19.52 crore)
Offer for sale Nil
Total IPO size 2,296,000 shares (INR19.52 crore)
Minimum bid (lot size) 1,600 shares
Face Value  INR10 per share
Retail Allocation 50%
Listing On NSE Emerge SME platform
Beta Drugs’ financial performance (in INR lakh)
FY2013 FY2014 FY2015 FY2016 FY2017
Total revenue 313.0 138.4 26.2 2,639.5 4,168.2
Total expenses 308.6 136.2 37.7 2,526.1 3,650.2
Profit after tax 4.4 2.2 11.4 113.4 517.9

Beta Drugs Limited
Village Nandpur
Himachal Pradesh-17410

Phone: +91 01795 236196
Email: [email protected]


Subscription (no. of times)

Day 1 0.08
Day 2 0.66
Day 3 17.87


Earnings Per Share (EPS): INR8.69

Price/Earnings (P/E) ratio: 9.78

Return on Net Worth (RONW): 70.18%

Net Asset Value (NAV): INR12.39 per share

Link Intime India Private Limited
C-101, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai – 400 083
Maharashtra, India

Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email[email protected]

Beta Drugs IPO allotment status is now available on Link Intime’s website. Click on this link to get allotment status.

IPO Opening Date: 29 September 2017

IPO Closing Date: 4 October 2017

Finalisation of Basis of Allotment: 9 October 2017

Initiation of refunds: 10 October 2017

Transfer of shares to demat accounts: 11 October 2017

Listing Date: 12 October 2017

Listing Price on NSE SME: INR102 per share (up 20% from IPO price)

Closing Price on NSE SME: INR101.95 per share (up 19.94% from IPO price)



Please enter your comment!
Please enter your name here